MEDP · Medpace Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $17.02B |
| P/E | 34.67 |
| Float | 22.38M |
| Beta | 1.11 |
| Volatility | 27.7% |
| Exchange | NASDAQ |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 74.8 |
| Price | 616.38 |
| Change | +1.06% |
| Prev Close | 609.89 |
| Open | 620.05 |
| Day Low | 609.48 |
| Day High | 620.75 |
| Avg Vol | 0 |
| Avg $ Vol | $147.7M |
| 52W High | 677.90 |
| 52W Low | 373.00 |
| 52W Pos | 79.8% |
| From High | −9.08% |
| From Low | +65.25% |
| Max DD 1Y | −36.61% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +0.33% |
| SMA 50 | +2.04% |
| SMA 200 | +17.32% |
| RSI (14) | 50.9 |
| Vol 30D | 26.9% |
| Vol 90D | 36.9% |
| 1Y Range | 373–678 |
| Daily bars | 533 |
| Perf Week | +1.16% |
| Perf Month | +2.43% |
| Perf Quarter | +15.24% |
| Perf Half Y | +17.29% |
| Perf Year | +21.68% |
| Perf YTD | +7.94% |
| Prev Day | +1.06% |
| Clavix | B |
| Debt / Eq | 0.36 |
| Curr Ratio | 0.74 |
| Int Cover | 100.5× |
| FCF Margin | 27.0% |
| Rev Growth | +20.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 9 / 19 |
Clavix risk grade
regraded every trading dayMEDP grades B, 74.8 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (58, mixed). 0 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 9 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.11 | 1.17 |
| Volatilityannualized | 27.7% | 29.3% |
| Max drawdown, past yearworst peak-to-trough fall | −36.6% | — |
| Typical daily movemedian absolute daily change | 1.13% | — |
| Days beyond ±3%of the last 252 sessions | 33 (13%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MEDP | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.11 | 1.17 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MEDP | |
|---|---|
| 1 week | +1.2% |
| 1 month | +2.4% |
| Year to date | +7.9% |
| 1 year | +21.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MEDP | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 9 since 25 Sep |
| Average score0 most bearish, 100 most bullish | 48 |
| Bullish · bearisharticles above 60 · below 40 | 3 · 5 |
| Directionarticles whose tone is improving vs worsening | 3 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| MEDP | |
|---|---|
| Revenue growthyear over year | +20.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openIn the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace's stock is being misread because the market sees its faster cleanup of its backlog of booked work as a sign growth is topping out, when the article argues it actually reflects higher-quality contracts. Q2 revenue rose 17.2% to $707.3M, the EBITDA margin improved underneath pass-through cost effects, and full-year 2026 guidance was raised for revenue, EBITDA, and EPS.
Avantor (NYSE:AVTR - Get Free Report) and Medpace (NASDAQ:MEDP - Get Free Report) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Risk and Volatility Avantor has a beta of 0.94, […]
Monument Capital Management purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,668 shares of the company's stock, valued at approximately
230-Page Report Shows How 569,000+ Registered Clinical Studies, CRO Consolidation and AI-Driven Trial Models Are Reshaping Outsourcing Strategy for Pharma and Biotech LeadersDublin, Oct. 08, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical CRO Market Size, Share & Trends Analysis Report by Type, Molecule Type, Services, Therapeutic Area, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical CRO market was valued at an estimated USD 45.33
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| RVTY | Revvity Inc | B | $17.30B | 73.02 | 1.09 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $14.27B | — | 1.38 | Compare |
| TEM | Tempus AI Inc | D- | $12.31B | — | 2.15 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 48.13 | 1.15 | Compare |
| TECH | Bio-Techne Corp | B | $11.37B | 62.55 | 1.28 | Compare |
| RGEN | Repligen Corp | B- | $11.14B | 264.15 | 1.12 | Compare |
| AVTR | Avantor Inc | B- | $10.52B | — | 0.98 | Compare |
| QGEN | Qiagen NV | B+ | $9.36B | 22.97 | 0.60 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.